Vistagen Therapeutics Past Earnings Performance
Past criteria checks 0/6
Vistagen Therapeuticshan disminuido a un ritmo medio anual de -22%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 17.2%.
Key information
-18.2%
Earnings growth rate
32.2%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 17.6% |
Return on equity | -26.0% |
Net Margin | -3,076.6% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis
Sep 08VistaGen drops 80% as late-stage study for anxiety therapy fails
Jul 22Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation
Apr 10VistaGen Therapeutics added to Russell 2000 Index
Jun 16VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business
Jun 07VistaGen initiates late-stage trial of PH94B in social anxiety disorder
May 26VistaGen names new chief commercial officer
May 04How Does VistaGen Therapeutics' (NASDAQ:VTGN) CEO Salary Compare to Peers?
Feb 16VistaGen Therapeutics regains Nasdaq listing compliance
Jan 06VistaGen Therapeutics slumps in after hours trade on underwritten public offering
Dec 17VistaGen reports encouraging data differentiating mechanism of action of PH94B from benzodiazepines
Nov 12Revenue & Expenses BreakdownBeta
How Vistagen Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 1 | -32 | 14 | 21 |
30 Sep 23 | 1 | -35 | 13 | 24 |
30 Jun 23 | 0 | -46 | 13 | 33 |
31 Mar 23 | 0 | -59 | 15 | 44 |
31 Dec 22 | 0 | -64 | 16 | 47 |
30 Sep 22 | 0 | -65 | 16 | 48 |
30 Jun 22 | 1 | -60 | 16 | 45 |
31 Mar 22 | 1 | -49 | 14 | 35 |
31 Dec 21 | 2 | -62 | 12 | 27 |
30 Sep 21 | 1 | -56 | 11 | 23 |
30 Jun 21 | 1 | -47 | 9 | 15 |
31 Mar 21 | 1 | -42 | 8 | 11 |
31 Dec 20 | 1 | -16 | 7 | 9 |
30 Sep 20 | 0 | -17 | 8 | 8 |
30 Jun 20 | 0 | -19 | 7 | 10 |
31 Mar 20 | 0 | -22 | 8 | 13 |
31 Dec 19 | 0 | -24 | 8 | 15 |
30 Sep 19 | 0 | -26 | 7 | 18 |
30 Jun 19 | 0 | -28 | 8 | 19 |
31 Mar 19 | 0 | -26 | 7 | 17 |
31 Dec 18 | 0 | -24 | 7 | 16 |
30 Sep 18 | 0 | -20 | 7 | 12 |
30 Jun 18 | 0 | -18 | 7 | 9 |
31 Mar 18 | 0 | -16 | 7 | 7 |
31 Dec 17 | 0 | -14 | 7 | 6 |
30 Sep 17 | 1 | -13 | 8 | 6 |
30 Jun 17 | 1 | -12 | 7 | 5 |
31 Mar 17 | 1 | -12 | 7 | 5 |
31 Dec 16 | 1 | -18 | 13 | 5 |
30 Sep 16 | 0 | -19 | 12 | 4 |
30 Jun 16 | 0 | -24 | 14 | 4 |
31 Mar 16 | 0 | -51 | 14 | 4 |
31 Dec 15 | 0 | -48 | 9 | 4 |
30 Sep 15 | 0 | -46 | 8 | 3 |
30 Jun 15 | 0 | -39 | 5 | 2 |
31 Mar 15 | 0 | -14 | 5 | 2 |
31 Dec 14 | 0 | -9 | 3 | 2 |
30 Sep 14 | 0 | -8 | 3 | 3 |
30 Jun 14 | 0 | -8 | 3 | 3 |
31 Mar 14 | 0 | -3 | 3 | 2 |
31 Dec 13 | 0 | -5 | 3 | 2 |
30 Sep 13 | 0 | -21 | 3 | 0 |
Beneficios de calidad: VTGN actualmente no es rentable.
Creciente margen de beneficios: VTGN actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: VTGN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 22% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de VTGN en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: VTGN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: VTGN tiene un Rendimiento de los fondos propios negativo (-99.53%), ya que actualmente no es rentable.